WO2008049919A3 - Inhibiteurs de kinase - Google Patents

Inhibiteurs de kinase Download PDF

Info

Publication number
WO2008049919A3
WO2008049919A3 PCT/EP2007/061542 EP2007061542W WO2008049919A3 WO 2008049919 A3 WO2008049919 A3 WO 2008049919A3 EP 2007061542 W EP2007061542 W EP 2007061542W WO 2008049919 A3 WO2008049919 A3 WO 2008049919A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
kinase inhibitors
rho kinase
relates
present
Prior art date
Application number
PCT/EP2007/061542
Other languages
English (en)
Other versions
WO2008049919A2 (fr
Inventor
Olivier Defert
Dirk Leysen
Rompaey Philippe Van
Original Assignee
Devgen Nv
Olivier Defert
Dirk Leysen
Rompaey Philippe Van
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Devgen Nv, Olivier Defert, Dirk Leysen, Rompaey Philippe Van filed Critical Devgen Nv
Publication of WO2008049919A2 publication Critical patent/WO2008049919A2/fr
Publication of WO2008049919A3 publication Critical patent/WO2008049919A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

La présente invention concerne de nouveaux inhibiteurs des kinases de la famille AGC, en particulier des composés de formule (I) ou (II), ou un stéréoisomère, un tautomère, un racémique, un métabolite, un pro ou pré-médicament, un sel, un hydrate ou un solvate de ceux-ci, dans lesquelles R1, R2, R4, R5, R7, R8, q s, L et Y ont le sens défini dans les revendications. La présente invention concerne en particulier des inhibiteurs de la ROCK, des compositions, en particulier des produits pharmaceutiques, comprenant de tels inhibiteurs et des utilisations de tels inhibiteurs pour le traitement et la prophylaxie de maladies.
PCT/EP2007/061542 2006-10-26 2007-10-26 Inhibiteurs de kinase WO2008049919A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85444506P 2006-10-26 2006-10-26
US60/854,445 2006-10-26
EP06447116 2006-10-26
EP06447116.2 2006-10-26

Publications (2)

Publication Number Publication Date
WO2008049919A2 WO2008049919A2 (fr) 2008-05-02
WO2008049919A3 true WO2008049919A3 (fr) 2008-07-03

Family

ID=39149206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/061542 WO2008049919A2 (fr) 2006-10-26 2007-10-26 Inhibiteurs de kinase

Country Status (1)

Country Link
WO (1) WO2008049919A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096569B2 (en) 2008-07-25 2015-08-04 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CN107903250A (zh) * 2017-12-31 2018-04-13 佛山市赛维斯医药科技有限公司 一种含吡啶和硝基噻吩结构的化合物、制备方法及其用途
CN107915717A (zh) * 2017-12-31 2018-04-17 佛山市赛维斯医药科技有限公司 一类含异丙基萘和丙二醇噻吩酰胺类化合物及其用途
CN107935986A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 异丙胺和卤代噻吩酰胺类结构化合物、其制备方法及用途
CN107935987A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 含甲基萘和噻吩酰胺结构的rock抑制剂、制备方法及其用途
CN108047193A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 烷氧噻吩酰胺类rock抑制剂、制备方法及其用途
CN108047214A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 一种含吡啶和硝基噻吩结构化合物及其用途
CN108047194A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 含甲基萘和丙二醇噻吩酰胺类化合物、制备方法及其用途
CN108191820A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种含异丙胺和噻吩酰胺类结构的化合物
US11590123B2 (en) 2016-08-31 2023-02-28 Aerie Pharmaceuticals, Inc. Ophthalmic compositions

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
CA2664335C (fr) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Inhibiteurs de la rho-kinase
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
EP3053913B1 (fr) 2009-05-01 2018-03-07 Aerie Pharmaceuticals, Inc. Inhibiteurs à double mécanisme pour le traitement d'une maladie
EP2332917B1 (fr) * 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Composés pour l'inhibition de kinase PIM et pour le traitement des tumeurs
US8785648B1 (en) 2010-08-10 2014-07-22 The Regents Of The University Of California PKC-epsilon inhibitors
US9409122B2 (en) 2011-04-18 2016-08-09 Commonwealth Scientific And Industrial Research Organisation Gas capture process
GB201107223D0 (en) * 2011-04-29 2011-06-15 Amakem Nv Novel rock inhibitors
CA2862831A1 (fr) * 2012-01-09 2013-07-18 X-Rx, Inc. Derives de tryptoline presentant une activite inhibitrice de kinase et utilisations de ceux-ci
CN105308031B (zh) * 2013-03-04 2017-10-13 健康科学北方研究所 喹啉磺酰基衍生物及其用途
CN109528721B (zh) 2013-03-15 2021-10-01 爱瑞制药公司 联合治疗
WO2016003450A1 (fr) * 2014-07-01 2016-01-07 The Regents Of The University Of California Inhibiteurs de pkc-epsilon
US10662183B2 (en) 2014-11-07 2020-05-26 The Regents Of The University Of Michigan Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
US10800745B2 (en) * 2017-08-18 2020-10-13 Purdue Research Foundation Methods for 1,4-diazo n-heterocycle synthesis
CN107973776A (zh) * 2017-12-31 2018-05-01 佛山市赛维斯医药科技有限公司 一种噻吩酰胺类结构化合物及其用途
CN108047197A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 硝基噻吩酰胺rock抑制剂、制备方法及其用途
CN108191819A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 异丙胺噻吩酰胺类结构化合物、其制备方法及用途
CN108558823A (zh) * 2017-12-31 2018-09-21 佛山市赛维斯医药科技有限公司 一类腈基噻吩酰胺rock抑制剂、制备方法及其用途
CN108101885A (zh) * 2017-12-31 2018-06-01 佛山市赛维斯医药科技有限公司 含异丙胺和硝基噻吩酰胺类结构化合物、其制备方法及用途
CN108129452A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 一种含异丙基萘和丙二醇硝基噻吩酰胺类化合物及其用途
CN107973777A (zh) * 2017-12-31 2018-05-01 佛山市赛维斯医药科技有限公司 一种含甲基萘和丙二醇噻吩酰胺类rock抑制剂及其用途
CN107936003A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 一类含吡啶和噻吩结构的化合物、制备方法及其用途
CN108129451A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 含丙二醇噻吩酰胺类化合物、制备方法及其用途
CN108047192A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 甲噻吩酰胺类结构化合物、其制备方法及用途
CN108047195A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 一种含丙二醇腈基噻吩酰胺类化合物及其用途
CN108218829A (zh) * 2017-12-31 2018-06-29 佛山市赛维斯医药科技有限公司 一种噻吩酰胺类rock抑制剂、制备方法及其用途
CN108148042A (zh) * 2017-12-31 2018-06-12 佛山市赛维斯医药科技有限公司 一类噻吩酰胺rock抑制剂、制备方法及其用途
CN108101884A (zh) * 2017-12-31 2018-06-01 佛山市赛维斯医药科技有限公司 含噻吩酰胺结构衍生物、制备方法及其用途
CN108033954A (zh) * 2017-12-31 2018-05-15 佛山市赛维斯医药科技有限公司 一种含吡啶结构的化合物、制备方法及其用途
CN108033953A (zh) * 2017-12-31 2018-05-15 佛山市赛维斯医药科技有限公司 一类含吡啶和烷氧噻吩结构的化合物、制备方法及其用途
CN108084149A (zh) * 2017-12-31 2018-05-29 佛山市赛维斯医药科技有限公司 含异丙基萘和丙二醇噻吩酰胺类化合物、制备方法及其用途
CN108129453A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 一种含甲基萘和丙二醇噻吩酰胺类结构的rock抑制剂
CN108047215A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 含吡啶结构的化合物、制备方法及其用途
CN108129449A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 一种含丙二醇噻吩酰胺类化合物、制备方法及其用途
CN108129448A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 噻吩酰胺类rock抑制剂、制备方法及其用途
CN108191821A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种含甲基萘和腈基噻吩酰胺类结构的rock抑制剂及用途
CN108129450A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 含烷氧噻吩酰胺和甲基萘结构的化合物、制备方法及其用途
US20210292766A1 (en) 2018-08-29 2021-09-23 University Of Massachusetts Inhibition of Protein Kinases to Treat Friedreich Ataxia
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005014A1 (fr) * 1991-09-05 1993-03-18 Pharno-Wedropharm Gmbh Derives aromatiques de sulfamide, leur utilisation en tant qu'inhibiteurs d'enzymes et compositions pharmaceutiques les contenant
WO2004092164A1 (fr) * 2003-04-10 2004-10-28 Amgen, Inc. Derives amines cycliques et leur utilisation dans le traitement de troubles lies a l'inflammation induits par la bradykinine
WO2005035503A1 (fr) * 2003-10-15 2005-04-21 Ube Industries, Ltd. Nouveau derive isoquinoline
EP1541559A1 (fr) * 2002-07-22 2005-06-15 Asahi Kasei Pharma Corporation Derive d'isoquinoline 5-substituee
WO2005080394A1 (fr) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. Derives de piperidine substitues en position 4
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005014A1 (fr) * 1991-09-05 1993-03-18 Pharno-Wedropharm Gmbh Derives aromatiques de sulfamide, leur utilisation en tant qu'inhibiteurs d'enzymes et compositions pharmaceutiques les contenant
EP1541559A1 (fr) * 2002-07-22 2005-06-15 Asahi Kasei Pharma Corporation Derive d'isoquinoline 5-substituee
WO2004092164A1 (fr) * 2003-04-10 2004-10-28 Amgen, Inc. Derives amines cycliques et leur utilisation dans le traitement de troubles lies a l'inflammation induits par la bradykinine
WO2005035503A1 (fr) * 2003-10-15 2005-04-21 Ube Industries, Ltd. Nouveau derive isoquinoline
WO2005080394A1 (fr) * 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. Derives de piperidine substitues en position 4
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096569B2 (en) 2008-07-25 2015-08-04 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US11590123B2 (en) 2016-08-31 2023-02-28 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CN107903250A (zh) * 2017-12-31 2018-04-13 佛山市赛维斯医药科技有限公司 一种含吡啶和硝基噻吩结构的化合物、制备方法及其用途
CN107915717A (zh) * 2017-12-31 2018-04-17 佛山市赛维斯医药科技有限公司 一类含异丙基萘和丙二醇噻吩酰胺类化合物及其用途
CN107935986A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 异丙胺和卤代噻吩酰胺类结构化合物、其制备方法及用途
CN107935987A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 含甲基萘和噻吩酰胺结构的rock抑制剂、制备方法及其用途
CN108047193A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 烷氧噻吩酰胺类rock抑制剂、制备方法及其用途
CN108047214A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 一种含吡啶和硝基噻吩结构化合物及其用途
CN108047194A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 含甲基萘和丙二醇噻吩酰胺类化合物、制备方法及其用途
CN108191820A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种含异丙胺和噻吩酰胺类结构的化合物

Also Published As

Publication number Publication date
WO2008049919A2 (fr) 2008-05-02

Similar Documents

Publication Publication Date Title
WO2008049919A3 (fr) Inhibiteurs de kinase
WO2007042321A3 (fr) Inhibiteur de kinase
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2007105058A8 (fr) Pyrazoles
IL184504A0 (en) 4-(2,6-dichlorobenzoylamino)-1h-pyrazole-3-carboxylic acid piperidin-4-ylamid acid addition salts as kinase inhibitors
WO2007049041A8 (fr) Derives 4-(3-aminopyrazole)pyrimidine et leur utilisation en tant qu'inhibiteurs de tyrosine kinases dans le cadre d'un traitement anticancereux
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
WO2009016460A8 (fr) Composés pyrazoles
WO2006047503A3 (fr) Inhibiteurs de la c-fms kinase
WO2008021369A3 (fr) Dérivés de composés tricycliques utiles dans le traitement de maladies néoplasiques, de troubles inflammatoires et de troubles immunomodulateurs
AP2470A (en) Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
WO2008039359A3 (fr) Inhibiteurs de pyrimidine kinase bicyclique
WO2010120994A3 (fr) Composés d'uréido-aryl-pyrimidine et de carbamoylaryl-morpholino-pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi-3, et leur synthèse
TNSN06405A1 (en) Quinazolinone derivatives useful as vanilloid antagonistes
WO2008128009A3 (fr) Aminopyrimidines utilisees en tant qu'inhibiteurs de kinases
TNSN08191A1 (en) Kinase inhibitors
PL2021335T3 (pl) Związki heterocykliczne jako inhibitory kinazy C-FMS
WO2008060476A3 (fr) Composés hétérocycliques contenant de l'azote et leurs procédés d'utilisation
WO2007136817A3 (fr) Aryl pipéridinylalcynyladénosines substituées en tant qu'agonistes de a2ar
WO2008057775A3 (fr) Composés d'amide hétérocyclique utiles comme inhibiteurs de kinase
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
WO2008046919A3 (fr) Composés hétérocycliques et leur utilisation comme inhibiteurs de la glycogène synthase kinase 3

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07821902

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07821902

Country of ref document: EP

Kind code of ref document: A2